

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AdvanCell Pty Ltd.
Petitioner

v.

Sciencons AS and ARTBIO, INC.,
Patent Owner

Post Grant Review No.: PGR2025-00040

PETITIONER'S REQUEST FOR ORAL ARGUMENT

Pursuant to 37 C.F.R. 42.70(a), Petitioner, AdvanCell Pty Ltd. requests oral argument on the issues set forth below at a place and time set by the Board. Oral argument is presently scheduled for July 23, 2026 (Paper No. 22, “Order Granting Requests to Change Oral Hearing Dates”).

Issues to be Presented by Petitioner at Oral Argument:

1. Proper construction of the relevant claims of the '437 patent;
2. The '437 patent is eligible for PGR;
3. Arguments and evidence that claims 1, 3-4, 7-12, 14-19, 22-26, 28-29, 31-32, 34-36, and 38 are anticipated by Hassfjell-Hoff;
4. Arguments and evidence that claims 1, 3-4, 7-12, 14-19, 22-26, 28-29, 31-32, 34-36, and 38 are rendered obvious by Hassfjell-Hoff;
5. Arguments and evidence that claims 1, 3, 5-7, 15-16, 18, 20-22, 29-33, and 35-37 are anticipated by Norman;
6. Arguments and evidence that claims 1, 3, 5-7, 15-16, 18, 20-22, 29-33, and 35-37 are rendered obvious by Norman;
7. Arguments and evidence that claims 1, 3-12, 14-26, and 28-38 are obvious over Hassfjell-Hoff and Norman;
8. Arguments and evidence that claim 2 is obvious over Hassfjell-Hoff and IAEA;

9. Arguments and evidence that claims 13 and 27 are obvious over Hassfjell-Hoff and Westrøm;
10. Arguments and evidence that claims 8-12, 14, 17, 23-26, 28, 34, and 38 are obvious over Norman and Hassfjell-Hoff;
11. Arguments and evidence that claims 13 and 27 are obvious over Norman, Hassfjell-Hoff, and Westrøm;
12. Arguments and evidence that claims 13 and 27 are obvious over Hassfjell-Hoff, Norman and Westrøm;
13. Arguments and evidence that claims 1-15 and 34-38 are unpatentable under 35 U.S.C. §112;
14. Whether the Board should accord any weight to the testimony of Patent Owner's expert, Mr. Conroy;
15. Rebuttal to Patent Owner's arguments and evidence on all matters including the issues listed above;
16. The timeliness of the arguments raised in the proceedings; and
17. Any other issues that the Board deems necessary for issuing a Final Written Decision, including any questions, rebuttals, or arguments that may arise during the oral argument.

Petitioner requests that the oral hearing take place at USPTO headquarters in Alexandria, VA.

Petitioner requests the ability to present demonstratives and exhibits to the Board.

Date: June 5, 2026

Respectfully submitted,

/s/ Jennifer Librach Nall

Jennifer Librach Nall

Reg. No. 57,053

DLA Piper LLP US

303 Colorado Street, Suite 3000

Austin, TX 78701

Phone: + 1 512 457 7249

Fax: + 1 512 721 2249

jennifer.nall.ptab@us.dlapiper.com

Attorney for Petitioner, AdvanCell
Isotopes Pty Ltd

CERTIFICATE OF SERVICE

The undersigned certifies that on June 5, 2026, a true and correct copy of the forgoing document was served by emailing a copy of same (by agreement) to the following attorneys for the Patent Owner:

Michael T. Rosato (mrosato@wsgr.com)

Patrick M. Medley (pmedley@wsgr.com)

Michael J. Hostetler (mhostetler@wsgr.com)

Respectfully submitted,

/s/ Jennifer Librach Nall

Jennifer Librach Nall